COLUMBIA, Mo. -- Low-density lipoproteins (LDL) — commonly known as bad cholesterol — have long been on scientists’ radar as a major contributor to heart disease. But these microscopic troublemakers ...
The results of a phase three clinical trial for a cholesterol-lowering drug have shown that this drug, called enlicitide, can reduce the levels of low-density lipoprotein (LDL) cholesterol by 60% ...
Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results